Schweitzer D H, Zwinderman A H, Vermeij P, Bijvoet O L, Papapoulos S E
Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands.
J Bone Miner Res. 1993 Feb;8(2):175-82. doi: 10.1002/jbmr.5650080208.
A group of 89 patients with Paget's disease of bone were treated with different intravenous or oral doses of the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate (dimethyl-APD). Biochemical remission was obtained in 82% of treatments, and in the rest a clear response was found. Oral dimethyl-APD was well tolerated, and a dose of 200 mg/day for 10 days was sufficient to induce remission in the majority of patients. The remission probability was 3 months for 50% of patients, and the recurrence-free period was 27 months. The remission probability as well as the recurrence-free period did not differ among oral and intravenous treatments or among patients who had never been treated with nitrogen-containing bisphosphonates and those who had received pamidronate in the past and were treated for a recurrence of the disease. Dimethyl-APD is a very effective bisphosphonate devoid of side effects, which given for a short period can induce long-lasting remissions in patients with Paget's disease of bone.
一组89例骨Paget病患者接受了不同静脉或口服剂量的含氮双膦酸盐二甲基氨基羟丙基二膦酸盐(二甲基-APD)治疗。82%的治疗获得了生化缓解,其余患者也有明显反应。口服二甲基-APD耐受性良好,200mg/天、连续10天的剂量足以使大多数患者获得缓解。50%的患者缓解概率为3个月,无复发期为27个月。口服和静脉治疗之间,以及从未接受过含氮双膦酸盐治疗的患者与过去接受过帕米膦酸盐治疗且因疾病复发而接受治疗的患者之间,缓解概率和无复发期均无差异。二甲基-APD是一种非常有效的双膦酸盐,无副作用,短期给药可使骨Paget病患者获得持久缓解。